NCT00084214已完成1 期
A Two-Stage Trial of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Metastatic Melanoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 103
- 试验地点
- 56
研究概览
简要总结
This study is designed to assess the efficacy of a weekly treatment regimen of STA-4783 and paclitaxel in comparison to paclitaxel alone on tumor response in metastatic melanoma patients.
详细描述
STA-4783 is a taxane potentiator, enhancing the effect of antitumor response of paclitaxel. In an attempt to improve efficacy, paclitaxel is sometimes used in combination with other anticancer agents. When paclitaxel is combined with other anticancer agents, although response rate is usually increased, side effects are usually increased as well. There is an urgent need for agents that can enhance the antitumor effects of paclitaxel without further increasing undesirable side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •M or F 18 or older with histologically confirmed metastatic (Stage IV) melanoma of cutaneous origin
- •ECOG performance status of greater than or equal to 2
- •Measurable disease per RECIST criteria
- •Received no more than 1 regimen of prior chemotherapy (unlimited immunotherapy regimens are allowed)
- •At least 4 weeks have passed since last chemotherapy or immunotherapy
- •At least 2 weeks have passed since last radiotherapy.
- •Life expectancy of greater than 12 weeks
- •Clinical lab values within protocol parameters
排除标准
- •Female patients pregnant or lactating
- •Female patients of childbearing potential not using or not willing to use effective contraception
- •Presence of a second malignancy other than nonmelanoma skin cancer
- •Presence of a clinically significant and uncontrolled infection
- •Presence of clinically significant arrythmias
- •Presence of serious concurrent illness or other conditions that do not permit adequate follow-up and compliance with protocol
- •History of severe hypersensitivity reactions to taxanes
- •Use of any investigational agents within 4 weeks prior to the first dose of study drug
研究者
研究点 (56)
Loading locations...
相似试验
已完成
2 期
A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue SarcomasSoft Tissue SarcomaNCT00087997Synta Pharmaceuticals Corp.80
终止
1 期
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung CancerExtensive Stage Small Cell Lung CancerNCT06016270STCube, Inc.10
已完成
3 期
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube CancerFallopian Tube CancerPrimary Peritoneal CancerOvarian CancerNCT01204749Amgen919
终止
2 期
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian CancerOvarian CancerNCT00585052University of Iowa11
已完成
2 期
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate CarcinomaProstate CancerNCT00193193SCRI Development Innovations, LLC100